Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245004 | 1.00 | KDM5A (0.47) | KDM5AHCRTR1HCRTR2PIK3CDPIK3CA | |
| SCHEMBL8226209 | 0.91 | HCRTR1 (0.45) | KDM5AHCRTR1HCRTR2EGFRITK | |
| SCHEMBL4246412 | 0.90 | HCRTR1 (0.48) | KDM5AHCRTR1HCRTR2PIK3CDPIK3CA | |
| SCHEMBL4246408 | 0.90 | HCRTR1 (0.48) | KDM5AHCRTR1HCRTR2PIK3CDPIK3CA | |
| SCHEMBL4249175 | 0.86 | NPC1 (0.47) | KDM5AHCRTR1HCRTR2PIK3CDPIK3CA | |
| SCHEMBL3653648 | 0.86 | NPC1 (0.47) | KDM5AHCRTR1HCRTR2PIK3CDPIK3CA | |
| SCHEMBL3658078 | 0.85 | HCRTR1 (0.62) | HCRTR1HCRTR2 | |
| SCHEMBL3658083 | 0.85 | HCRTR1 (0.62) | HCRTR1HCRTR2 | |
| SCHEMBL8224436 | 0.85 | HCRTR1 (0.45) | KDM5AHCRTR1HCRTR2 | |
| SCHEMBL4247661 | 0.83 | HCRTR1 (0.47) | KDM5AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | claimed |
| EP-2234999-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | claimed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | claimed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | claimed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2234999-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | KDM5A 2654/4885HCRTR1 1/4885HCRTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.